Covid-19 Resources
Latest CDC/WHO/AAFP Recommendations
Latest Covid News

July 13, 2022

COVID-19: Novavax Vaccine, Adjuvanted — New Codes

The FDA authorized emergency use of the Novavax COVID-19 vaccine, Adjuvanted for the prevention of COVID-19 disease in patients 18 years and older.

July 06, 2022

Coronavirus (COVID-19) Update: FDA Authorizes Pharmacists to Prescribe Paxlovid with Certain Limitations | FDA

Today, the U.S. Food and Drug Administration revised the Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir and ritonavir), to authorize state-licensed pharmacists to prescribe Paxlovid to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing of Paxlovid.
More Covid News

July 06, 2022

COVID-19: FDA Authorizes Pharmacists to Prescribe PAXLOVID with Certain Limits

The FDA issued an emergency use authorization (EUA) for PAXLOVID (nirmatrelvir co-packaged with ritonavir) for the treatment of mild-to-moderate COVID-19 in certain adults and pediatric patients at high risk for progression to severe COVID-19, including hospitalization or death.

June 17, 2022

COVID-19: Pfizer-BioNTech Vaccines for Children as Young as 6 Months — New Codes

The FDA amended the Pfizer-BioNTech COVID-19 vaccine emergency use authorization (PDF) to authorize use for all patients 6 months – 4 years old. Get important vial and dosing information. CMS issued new CPT codes effective June 17, 2022.

May 25, 2022

FDA New Checklist for Paxlovid

The FDA released a new checklist to help clinicians determine which patients are eligible for Paxlovid, an oral antiviral for mild to moderate COVID-19 in adults and some pediatric patients who are at high risk for severe COVID-19. The agency also updated a Paxlovid fact sheet with more specific recommendations.

May 17, 2022

COVID-19: New Administration Code for Pfizer Pediatric Vaccine Booster Dose

The FDA amended the Pfizer-BioNTech COVID-19 vaccine emergency use authorization (PDF) to authorize the use of a single booster pediatric dose (orange cap) for all patients 5–11 years old. CMS issued a new code, effective May 17, 2022, for the vaccine administration: Code: 0074A